Overview | Capital Markets | Sullivan & Worcester

Capital Markets

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley

Neural Input Technology Company, Wearable Devices Ltd. IPO

Sullivan represented Wearable Devices Ltd., a growth company developing a non-invasive neural input interface technology in the form of a wrist wearable band for controlling digital devices using subtle finger movements for B2B and B2C customers, in its $16 million initial public offering. Wearable Devices is based in Israel and aims to create a world in which the user’s hand becomes a universal input device for touchlessly interacting with technology, and that their technology is setting the standard input interface for the Metaverse.

Howard E. Berkenblit, Oded Har-Even, Tamilla Nurizada and Ilana Neck Levin

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

We excel in the flawless execution required in a range of financing transactions in both equity and debt and in securities law compliance, providing experienced and nuanced counsel in all transaction types, a variety of markets, and in all market conditions. Clients appreciate our responsiveness to their needs, including disclosure, reporting, and enforcement issues. In addition to U.S.-based companies, we have extensive experience representing foreign issuers globally and providing them with securities law and capital markets advice.

Our clients comprise a wide range of publicly traded and privately owned businesses, foreign companies and sources of equity capital and debt financing, such as banks, financial institutions, and individual or institutional investors. Our global capital markets team routinely executes on a full range of financing transactions, including, among others:

Initial public offerings (IPOs)
Follow-on/secondary public offerings
Venture capital investments
Private placements of securities
Convertible/equity-linked offerings
Strategic partnerships
SPACs and de-SPAC transactions
Digital asset and tokenized securities offerings
Spin-offs
ATM and ELOCs
Public M&A-related listings and compliance

We also regularly prepare registration statements for our issuer clients, handle their periodic SEC filings, handle stock exchange listings and overall manage compliance with rules and regulations governing every aspect of the capital markets ecosystem.

Clients

We represent publicly traded and privately owned businesses (including foreign companies who trade or raise capital in the U.S.), broker dealers and investment firms. Supplementing our core capital markets practice, we have capital markets attorneys who enjoy a particular subject matter expertise in the REITs, technology and the biotech sectors. Our capital markets lawyers routinely handle transactions around the globe, including across Israel and the Middle East, Asia and Europe. We routinely advise boards of directors and company officers in securities transactions and corporate governance matters.

We help clients meet the challenges and obligations of complying with a myriad of state and federal rules, including Blue Sky compliance, Sarbanes-Oxley, Dodd-Frank and stock exchange listing standards. We counsel boards of directors and their committees on:

Fiduciary duties
Executive compensation
Company policies and procedures
Insurance
Whistleblower complaints
Bylaw provisions
Clawback policies
Risk management
Auditor independence
Internal control over financial reporting; and
Other compliance issues

With experienced lawyers from multiple, seamlessly connected departments within the firm, we represent management, boards, audit and other committees, as well as individual executives, employees and directors. We also provide corporate governance counseling for mutual funds and their directors through our Investment Management Group.

Representative Client Work

Our recent experience includes two senior debt offerings by REITs and an offering of American Depositary Shares by a manufacturer of 3D printers for electronic circuit boards. Total gross proceeds raised in these offerings are nearly $1.5 billion (on top of the over $10 billion we helped our clients raise in the past three years in the public markets).

Here is a selected sample of recent Capital Markets clients and experience:

Securities

Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock, and placement agent counsel in a $425 million private placement of common stock, by a global marketing partner to leading sportsbooks and online casino gaming operators
Issuers or underwriters in numerous IPOs in the biotechnology and technology industries
Office, government properties, senior living and hotel REITs in raising tens of billions of dollars in public and 144A offerings of common equity, straight and convertible preferred equity and senior and convertible debt
Ongoing disclosure, governance and listing advice to Iron Mountain Incorporated, including public and 144A equity and debt offerings
Represented FINRA placement agent in registered direct for a Chinese biotechnology company focusing on early cancer screening and detection
Represented REIT as issuer in first initial public offering (IPO)
Facilitated senior subordinated debt placements denominated in British Pounds Sterling (GPB), Canadian dollars (CAD) and Euro (EUR) for a U.S. public company; provided ongoing disclosure, corporate governance and stock exchange listing advice for same public client
Public senior living community operator in a convertible note offering
Lead underwriter in several follow-on public equity offerings by a biotech company
Public companies acquisitions with both registered and unregistered stock consideration
Various companies in self-tender offers for outstanding notes
A private financial services firm in a $700 million 144A debt offering
A foreign software company in an acquisition and a going private transaction involving U.S. software company
A REIT in an acquisition and public spinoff of a travel center company
A biotech company in multiple "registered direct" offerings of common stock and warrants
A medical devices company traded on the Tel Aviv Stock Exchange in its ADR listing on Nasdaq followed by a $47 million public offering
Software and technology companies in equity and convertible note PIPEs
A financial services company in switching its listing from Nasdaq to NYSE
Companies whose shares were quoted on the OTC markets with uplisting to Nasdaq

Corporate Governance

Ensured observance of Sarbanes-Oxley Act requirements and stock exchange listing standards
Advised on financing alternatives under the JOBS Act
Developed compliance charters, policies and procedures for issuer's board of directors/management
Counseled board committees and independent directors
Offered guidance on procedures for and responses to whistleblower allegations
Advised on adoption of executive compensation "clawback" policy
Facilitated development and oversight of executive compensation plans
Developed disclosure and social media policies
Counseled officers and directors on fiduciary duties and state law governance practices

Client Highlights

All Client Highlights

Neural Input Technology Company, Wearable Devices Ltd. IPO

Viewpoints

All Viewpoints

SEC Approves Nasdaq's New $5 Million Market Capitalization Threshold for Continued Listing

On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved Nasdaq's amended proposed rule for a new continued listing requirement requiring Nasdaq-listed companies to maintain a minimum Market Value of Listed Securities (“MVLS”) of $5 million. The SEC approved the proposal as modified by Amendment No. 1 following a lengthy process that generated significant comments from market participants, issuers, investors, exchanges, law firms, and industry groups. The new rule will have a particularly pernicious impact on micro-cap, small-cap and development-stage public companies. Companies that fail to maintain an MVLS of at least $5 million for 30 consecutive business days will be subject to immediate suspension and delisting procedures, without the benefit of the traditional cure period available for many other Nasdaq continued listing deficiencies. Overview of the New Requirement Under the approved rule, Nasdaq-listed companies on the Nasdaq Capital Market, Nasdaq Global Market and Nasdaq Global Select Market must maintain an MVLS of at least $5 million. MVLS is generally calculated as the consolidated closing bid price multiplied by the number of listed securities outstanding. If a company's MVLS remains below $5 million for 30 consecutive business days: Nasdaq will issue a Staff Delisting Determination (“Staff Delisting Determination”). The company will not receive a compliance or cure period. Trading in the company's securities will be suspended from Nasdaq. The company will generally trade on the over-the-counter market while pursuing any appeal rights. This represents a significant departure from Nasdaq's traditional approach to continued listing deficiencies, many of which provide issuers with a compliance period to regain compliance while remaining listed. Amendment No. 1: Limited Relief Through Hearings Panel Review In response to comments received during the rulemaking process, Nasdaq amended its proposal to provide a limited avenue for relief. Under new Nasdaq Rule 5815(c)(1)(I), a Nasdaq Hearings Panel may grant an exception of up to 180 days from the Staff Delisting Determination if the company demonstrates that it can satisfy Nasdaq's initial listing standards. The Hearings Panel also retains authority to reverse a delisting determination if Nasdaq staff acted in error. Importantly, however: The exception is discretionary. Suspension from Nasdaq trading is not automatically stayed during the appeal. The issuer generally must demonstrate compliance with Nasdaq's initial listing standards, which are more stringent than Nasdaq's continued listing standards. Accordingly, while Amendment No. 1 provides a modest additional procedural mechanism, companies should not view it as a substitute for proactively addressing potential listing compliance concerns. SEC's Rationale for Approval The SEC concluded that the new rule is consistent with Section 6(b) the Securities Exchange Act of 1934 and agreed with Nasdaq's position that issuers with an MVLS below $5 million may present heightened risks of manipulation and challenges to maintaining fair and orderly markets. In approving the rule, the SEC relied in part on its own historical analysis, which found that many issuers that remained below the $5 million threshold for 30 consecutive business days continued to trade below that level for extended periods and were frequently later delisted for other quantitative listing deficiencies. Although the SEC acknowledged comments noting that some issuers ultimately recover after temporarily falling below the threshold, it determined that the investor protection benefits of the rule, together with the limited relief provided by Amendment No. 1, supported approval. Practical Considerations for Nasdaq Issuers The new rule creates a material compliance risk for many smaller public companies, particularly those operating in capital-intensive industries such as biotechnology, life sciences, technology, energy transition and other emerging growth sectors. Companies should consider implementing enhanced monitoring procedures to track MVLS on an ongoing basis and evaluate potential corrective actions before a deficiency develops. Potential considerations may include: Capital raising transactions. Strategic transactions or business combinations. Balance sheet recapitalizations. Alternative listing or trading strategies. Other corporate actions designed to improve compliance with Nasdaq's quantitative standards. Because the MVLS calculation is based on market capitalization, often coupled with other listing metrics such as bid price, stockholders' equity, market value of publicly held shares and public float requirements, compliance planning should be evaluated holistically and on a company-specific basis. What Public Companies Should Do Now Nasdaq-listed companies, particularly those with market capitalizations approaching the $5 million threshold, should evaluate the potential impact of the new rule immediately. Companies should consider: Reviewing their current and projected MVLS levels. Assessing compliance with all Nasdaq continued listing standards. Evaluating available capital markets and corporate finance alternatives. Developing contingency plans for potential listing deficiencies. Understanding the implications of a suspension and OTC market transition. Evaluating whether actions can be taken now to strengthen listing compliance and capital market flexibility. The final rule did not set an effectiveness date nor advise issuers whether there would be a phase-in period for complying with the rule, the assumption being that it is effective immediately. For More Information Sullivan & Worcester LLP has been actively involved in advising issuers regarding Nasdaq listing standards, continued listing compliance, capital raising transactions, recapitalizations, exchange matters and SEC regulatory developments. Questions regarding the new MVLS requirement, its potential impact on an issuer's continued Nasdaq listing, the impact on a portfolio company, or available alternatives to address potential compliance concerns, may be directed to your regular Sullivan & Worcester attorney or any member of our Corporate and Securities Practice Group. This Client Alert has been prepared by David Danovitch, a Partner, Angela Gomes, a Partner, Brendan O'Brien, a Partner, and Phillip Carnevale, an Associate, in the Corporate and Securities practice group of the international law firm of Sullivan & Worcester LLP. For more information, Mr. Danovitch may be reached in our New York office by calling +1 (212) 660-3060 or by email at ddanovitch@sullivanlaw.com; Ms. Gomes may be reached in our Boston office by calling +1 (617) 338-2957 or by email at agomes@sullivanlaw.com; Mr. O'Brien may be reached in our New York office by calling +1 (212) 660-3013 or by email at bobrien@sullivanlaw.com; and Mr. Carnevale may be reached in our New York office by calling +1 (212) 660-3002 or by email at pcarnevale@sullivanlaw.com. This Client Alert is provided for general informational purposes only and does not constitute legal advice.

SEC Establishes Retail Fraud Working Group to Combat Fraud Targeting Everyday Investors

The U.S. Securities and Exchange Commission (“SEC”) announced on July 7, 2026, the creation of the Retail Fraud Working Group, a new initiative within the Division of Enforcement designed to identify and combat fraud targeting main street investors. The announcement formalizes a priority that SEC Enforcement Director David Woodcock previewed in his May 13, 2026, remarks to the Managed Funds Association Legal & Compliance Conference, reflecting the current Commission’s broader back-to-basics enforcement posture. For issuers, broker-dealers, investment advisers, and private fund managers with retail exposure, the announcement signals that retail-facing enforcement will be a sustained focus of the Division’s work in the months and years ahead. Overview The Retail Fraud Working Group will leverage staff and resources across the Commission to identify fraud and other misconduct targeting retail investors, including offering frauds, pump-and-dump schemes, market manipulation, and breaches of duties owed to customers by investment advisers and broker-dealers. The Group’s initiative is threefold: (i) to serve as a dedicated resource to proactively generate cases; (ii) to work with the Commission’s domestic regulatory partners and foreign counterparts; and (iii) to assist with educating retail investors in coordination with the SEC’s Office of Investor Education and Assistance. The Group will be led by Kate Zoladz, Deputy Director, West, and Kim Frederick, Assistant Director of the Asset Management Unit. Ms. Frederick’s role in the Asset Management Unit suggests that adviser and private fund conduct affecting retail investors will be a focus area for the Group. Chairman Paul S. Atkins described the initiative as “a return to the core values and principles of the enforcement program,” and Director Woodcock emphasized the Group’s role in “generating cases, building partnerships with our regulatory counterparts, and using data and technology to find and stop those who seek to take advantage of retail investors.” About Our Small-Firm Task Force Sullivan & Worcester’s Small-Firm Task Force is actively engaged in advising clients on the implications of the Retail Fraud Working Group and can assist with responding to any related SEC inquiries. The Task Force unites the firm’s Capital Markets, Regulatory Compliance, Government Investigations, and Financial Services Litigation practices, each with deep experience advising issuers, broker-dealers, investment funds, and institutional investors in the small-cap, micro-cap, and mid-market segments. Our interdisciplinary team is well-positioned to help clients navigate the SEC’s renewed retail-fraud enforcement priorities and to develop practical, risk-based compliance strategies aligned with the current regulatory environment.

News

All News

Sullivan Advises Lake Street Capital Markets as Underwriter on $25 Million NeoVolta Public Offering

Sullivan served as underwriter’s counsel to Lake Street Capital Markets, LLC in connection with the pricing of a $25.0 million public offering of common stock by NeoVolta Inc. (Nasdaq: NEOV), a U.S.-based energy technology company delivering scalable energy storage solutions. The offering consisted of 12,195,122 shares of common stock priced at $2.05 per share, generating gross proceeds of approximately $25.0 million before deducting underwriting discounts, commissions, and offering expenses. NeoVolta also granted the underwriter a 30-day option to purchase up to an additional 1,829,268 shares at the public offering price, less underwriting discounts and commissions. Lake Street Capital Markets acted as sole book-running manager for the offering, which was conducted pursuant to NeoVolta’s effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission. The offering closed on May 29. The Sullivan team consisted of Angela Gomes, David Danovitch, Michael DeDonato, Zachary Sobel and Karly Roux. Read the full pricing press release here.

Sullivan Advises Somatix in Merger with Vitalist

Sullivan advised long-time client Somatix, a digital health company specializing in wearable-based patient monitoring solutions, in connection with its acquisition by Vitalist, a health technology company focused on longevity and preventive care, in an all-stock merger transaction. The transaction positions the combined company to advance its capabilities in digital health and remote patient monitoring, supporting continued innovation and growth in the sector. The team advising Somatix was led by Scott Kaufman and Alexander Gansebom, supported by Sullivan attorneys Tamir Chagal, Michael Palmisciano, Amy Sheridan, Douglas Stransky, Erika Todd, Eric Victorson, Janice Lee and Eric Rietveld. Read the full press release here.

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Initial public offerings (IPOs)
Follow-on/secondary public offerings
Venture capital investments
Private placements of securities
Convertible/equity-linked offerings
Strategic partnerships
SPACs and de-SPAC transactions
Digital asset and tokenized securities offerings
Spin-offs
ATM and ELOCs
Public M&A-related listings and compliance

Clients

Fiduciary duties
Executive compensation
Company policies and procedures
Insurance
Whistleblower complaints
Bylaw provisions
Clawback policies
Risk management
Auditor independence
Internal control over financial reporting; and
Other compliance issues

Representative Client Work

Here is a selected sample of recent Capital Markets clients and experience:

Securities

Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock, and placement agent counsel in a $425 million private placement of common stock, by a global marketing partner to leading sportsbooks and online casino gaming operators
Issuers or underwriters in numerous IPOs in the biotechnology and technology industries
Office, government properties, senior living and hotel REITs in raising tens of billions of dollars in public and 144A offerings of common equity, straight and convertible preferred equity and senior and convertible debt
Ongoing disclosure, governance and listing advice to Iron Mountain Incorporated, including public and 144A equity and debt offerings
Represented FINRA placement agent in registered direct for a Chinese biotechnology company focusing on early cancer screening and detection
Represented REIT as issuer in first initial public offering (IPO)
Facilitated senior subordinated debt placements denominated in British Pounds Sterling (GPB), Canadian dollars (CAD) and Euro (EUR) for a U.S. public company; provided ongoing disclosure, corporate governance and stock exchange listing advice for same public client
Public senior living community operator in a convertible note offering
Lead underwriter in several follow-on public equity offerings by a biotech company
Public companies acquisitions with both registered and unregistered stock consideration
Various companies in self-tender offers for outstanding notes
A private financial services firm in a $700 million 144A debt offering
A foreign software company in an acquisition and a going private transaction involving U.S. software company
A REIT in an acquisition and public spinoff of a travel center company
A biotech company in multiple "registered direct" offerings of common stock and warrants
A medical devices company traded on the Tel Aviv Stock Exchange in its ADR listing on Nasdaq followed by a $47 million public offering
Software and technology companies in equity and convertible note PIPEs
A financial services company in switching its listing from Nasdaq to NYSE
Companies whose shares were quoted on the OTC markets with uplisting to Nasdaq

Corporate Governance

Ensured observance of Sarbanes-Oxley Act requirements and stock exchange listing standards
Advised on financing alternatives under the JOBS Act
Developed compliance charters, policies and procedures for issuer's board of directors/management
Counseled board committees and independent directors
Offered guidance on procedures for and responses to whistleblower allegations
Advised on adoption of executive compensation "clawback" policy
Facilitated development and oversight of executive compensation plans
Developed disclosure and social media policies
Counseled officers and directors on fiduciary duties and state law governance practices

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

Capital Markets

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Neural Input Technology Company, Wearable Devices Ltd. IPO

Capital Markets

SEC Approves Nasdaq's New $5 Million Market Capitalization Threshold for Continued Listing

SEC Establishes Retail Fraud Working Group to Combat Fraud Targeting Everyday Investors

Sullivan & Worcester Submits Rebuttal Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

SEC Proposes Significant Changes to Public Company Reporting Rules, Including New Filer Categories and Expanded Disclosure Relief

SEC Proposes Reforms to Registered Offering Framework

Sullivan & Worcester Submits Supplemental Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

SEC Proposes Optional Semiannual Interim Reporting Framework

Nasdaq Considers a New $5 Million Market Value Threshold for Continued Listing: What Issuers Need to Know

Sullivan & Worcester Submits Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement

Foreign Private Issuers’ Directors and Officers to Be Subject to Section 16 Reporting

SGX-Nasdaq Dual Listing Framework - Opening New Doors for East Asian Companies

FINRA’s Small-Cap Sweep: Strategic Steps for Broker-Dealers

FINRA Launches Targeted Review of Small-Cap Foreign Offerings

Sullivan & Worcester Submits Comment to SEC on Foreign Private Issuer Definition

SEC Expands Confidential Submission Options for Issuers to Facilitate Capital Raising

New SEC Guidance May Lead to More 5% Shareholders Having to File Schedule 13Ds

SEC Approves NYSE and NYSE American Rule Changes Regarding Minimum Price Criteria Compliance Periods and the Use of Reverse Stock Splits

Nasdaq Changes Rules Regarding Minimum Bid Price Compliance Periods and Restricts the Use of Reverse Stock Splits

How I Made Partner: 'Focus on Being Excellent, Taking Responsibility and Ownership of Matters,' Says Meghan Rohan of Sullivan & Worcester

SEC and CFTC Continue Their Lucrative Pursuits of Penalizing Unapproved Communication Methods

Distressed Debt Investors Beware of Disqualified Lender Lists

SEC Amends Deadlines and Other Rules for Reporting Beneficial Ownership on Schedules 13D and 13G

SEC Adopts Rules for Cybersecurity Disclosures

SEC Adopts Amendments to Share Repurchase Disclosure

The SEC’s Stacked Deck Is News to Unsuspecting 'Dealers'

SEC Adopts Amendments to Modernize Rule 10b5-1 Insider Trading Plans and Related Disclosures

SEC Adopts Rules Requiring Compensation Clawback Policies

SEC Adopts Pay Versus Performance Disclosure Rules

How I Made Partner: 'The Firm Was Familiar With My Practice, Experience and Abilities,' Says Angela Gomes of Sullivan & Worcester

How Do You Keep a Company Alive in a Lull Market?

Capital Markets

Sullivan Advises Lake Street Capital Markets as Underwriter on $25 Million NeoVolta Public Offering

Sullivan Advises Somatix in Merger with Vitalist

SEC Turns the Spotlight On Nasdaq Delisting Standards

Sullivan & Worcester Announces Six Partner Elevations in Boston and New York

Atkins Calls for Leaner Corporate Risk Disclosures, Says Filings Have Become Litigation Shields

Sullivan's Capital Markets Team Recognized by IFLR1000 Middle East

Sullivan & Worcester Attorneys Named to 2025 Top Lawyers List by Boston Magazine

SEC, FINRA Cross-Border Crackdown Typifies Trump 2.0 Priorities

Sullivan Attorneys Selected to 2025 Massachusetts Super Lawyers and Rising Stars Lists

Sullivan & Worcester Announces Creation of Small-Firm Task Force to Address Latest FINRA Small-Cap IPO Sweep

Sullivan & Worcester Associate Chinyere S. Okogeri Selected for 2025 ACG Boston Accelerator Program

Many Foreign Firms Could Face Stricter Access To US Markets

Sullivan & Worcester Hires Fried Frank REIT Tax Pro

Sullivan Expands REIT and Tax Practices with New Partner in D.C.

Irish Firms 'Very Attractive to Investors' – Leading Law Firm Highlights Benefits of US Capital Markets

Sullivan & Worcester Attorneys Named to 2024 Top Lawyers List by Boston Magazine

Sullivan Attorneys Named 2024 Massachusetts Super Lawyers and Rising Stars

Sullivan Ranks High in PlacementTracker's Q2 2024 PIPE and Private Placement Markets League Tables

Brian Hurley Accepted Into the Association for Corporate Growth (ACG) Accelerator Program

Angela Gomes Selected as a 2024 Honoree for the Women's Bar Association's Pioneering Women of Color Celebration

SEC Has Careful Eye On Disclosures Amid Israel-Hamas War

Sullivan, One of the Top 200 Law Firms in the US, Wants to Help Irish Companies Raise Capital in America

Sullivan Attorneys Named to 2023 Top Lawyers List by Boston Magazine

Sullivan & Worcester Ranked by Best Law Firms® in 2024

Sullivan Attorneys Named 2023 Massachusetts Super Lawyers and Rising Stars

Israeli Future of Fem-Tech Healthcare Event

Rule Hastening Disclosure of Cyber Breaches Likely to Ignite Litigation, Insurance Headaches

43 Sullivan & Worcester Attorneys Listed in Best Lawyers in America® 2024 Edition

Sullivan & Worcester Names Corporate Partner David Danovitch New Office Managing Partner for New York City

Johanna Colpritt Accepted into the Association of Corporate Growth (ACG) Accelerator Program

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

U.S. and foreign businesses rely on Sullivan's Capital Markets group to handle sophisticated financial transactions worldwide. Clients seek our experienced counsel, practical business acumen, international finance connections, and ability to balance legal and business risks.

Clients

Representative Client Work

Capital Markets

SEC’s Increased Scrutiny of Climate Risk and Disclosures Likely to Lead to Agency Rulemaking